Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Bottom Line: Cognitive outcomes remained higher in the early treated patients.EDSS remained low over time with a median of 1.5 in both arms.These 8-year results provide further evidence supporting early initiation of treatment with IFNB1b in patients with a first event suggestive of MS.
Affiliation: University of Rennes, Rennes, France.Show MeSH
Related in: MedlinePlus
Mentions: At the end of the 8-year observational period, the risk for development of CDMS in the early treatment group was lower than that of the delayed treatment group by 32.2% (HR 0.678, 95% CI 0.525 to 0.875; p=0.0030, log-rank test; figure 2). Based on Kaplan–Meier estimates, early treatment with IFNB1b reduced the probability of the development of CDMS over the 8 years (55.5% early treatment vs 65.8% delayed) with differences emerging between the treatment arms in the first year. At the 50th percentile, IFNB1b prolonged the time to CDMS by 1345 days (3.7 years, 95% CI 389 to 2301; 2335 days (6.5 years) in the early versus 990 days (2.8 years) in the delayed treatment group.